cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Sony Eka Nugraha
Contact Email
Idkpcr@usu.ac.id
Phone
+62823 7049 2800
Journal Mail Official
idjpcr@usu.ac.id
Editorial Address
TALENTA Publisher Universitas Sumatera Utara cq.Indonesian Journal of Pharmaceutical and Clinical Research Faculty of Pharmacy Univesitas Sumatera Utara Jalan Tri Dharma No. 5, Pintu 4, Kampus USU Padang Bulan Medan 20155, Sumatera Utara - Indonesia
Location
Kota medan,
Sumatera utara
INDONESIA
Indonesian Journal of Pharmaceutical and Clinical Research
Published by Universitas Sumatera Utara
ISSN : 26156199     EISSN : 26203731     DOI : https://doi.org/10.32734/idjpcr.v1i1.203
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health
Indonesian Journal of Pharmaceutical and Clinical Research (IDJPCR) is a-peer-reviewed publication of original research works. The mission of the journal is to offer a medium to exchange ideas and information about the advancement of knowledge and research in disciplines of pharmaceutical technology, pharmacology, clinical pharmacy, medical sciences, biological pharmacy and pharmaceutical chemistry. The journal also receives systematic reviews, meta-analysis and review article on new issues in pharmaceutical and clinical sciences. Submission to this journal implies that the manuscript has not been published or under consideration to be published in another journal. At the initial stage, this journal will be published online twice a year.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics (Lain-Lain)
Articles 6 Documents
 1 
Search results for , issue "Vol. 4 No. 2 (2021): Indonesian Journal of Pharmaceutical and Clinical Research (IDJPCR) Vol. 04, No" : 6 Documents clear
Beneficial Role of Mushroom in Recovering Complications of Hypercholesterolemia Swarup Kumar Kundu; Md. Abu Hadi Noor Ali Khan; Shonkor Kumar Das
Indonesian Journal of Pharmaceutical and Clinical Research Vol. 4 No. 2 (2021): Indonesian Journal of Pharmaceutical and Clinical Research (IDJPCR) Vol. 04, No
Publisher : Talenta Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/idjpcr.v4i2.6467

Abstract

Mushrooms are considered as a valuable source of important nutrients having hepatoprotective and anti-hyperlipidemic actions. Present experimental research was done to explore the beneficial role of mushroom on health in hypercholesterolemia. Total thirty Swiss albino mice were taken and randomly divided into three groups: control A, group B and group C. Each group consisted of ten mice. The control A group was fed with normal mice pellet and fresh water. Group B was fed with hypercholesterolemic diet and group C was supplied hypercholesterolemic diet with mushroom powder (500g/kg/mice body weight) for 60 days. After the experimental tenure, mice of each group were sacrificed ethically and the samples (liver and blood) were collected for gross, histological study and lipid profile analysis.  Increased liver weight, pale and hemorrhagic liver in gross observation along with some histological changes including dilation and congestion of central and portal vein, fat accumulation in hepatocyte and marked lymphocytic infiltration were found in group B, while mushroom supplementation recovered this gross and histological changes and reduced liver weight in group C. Just mild congestion and dilation was in the portal vein of group C. In lipid profile analysis, total cholesterol (TC), triglyceride (TG) and low density lipoprotein (LDL) level significantly reduced respectively by 10%, 38% and 17% in group C than group B. High density lipoprotein (HDL) level also significantly increased by 20% in group C compared to group B. Therefore, it can be concluded that mushrooms might have potentially beneficial actions in recovering of some complications in hypercholesterolemia.
Antibacterial Activity of Patch Silver Nanoparticles and Chitosan with Cellulose Nanofibers Carriers against Staphylococcus aureus and Escherichia coli Andre Prayoga; Poppy Anjelisa Zaitun Hasibuan; Yuandani
Indonesian Journal of Pharmaceutical and Clinical Research Vol. 4 No. 2 (2021): Indonesian Journal of Pharmaceutical and Clinical Research (IDJPCR) Vol. 04, No
Publisher : Talenta Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/idjpcr.v4i2.6169

Abstract

One of the medical needs whose demand continues to increase is wound dressings. The wound cover must also be non-toxic, non-allergenic, made of widely available biomaterials, and have antibacterial properties that can prevent infection of the wound. Chitosan is known to have wound healing activity by acting as a blood-clotting agent and stimulating the formation of new tissue, and silver nanoparticles have good antibacterial activity. Silver Nanoparticles and Chitosan with Cellulose Nanofibers carriers (SNCCN) are made in the form of patches with the ratio formula between cellulose nanofibers and chitosan/silver nanoparticles is 1:9, 2:8, 3:8, 4:7, 5:5, 6:4, 7:3, 8:2, 9:1, and 10:0. Then the antibacterial activity was tested against Staphylococcus aureus and Escherichia coli to find the best formula for antibacterial activity. The analysis showed that the SNCCN patch with a ratio of 9:1 had the best antibacterial activity against Staphylococcus aureus (13.8±0.05 mm) and Escherichia coli (12.5±0.05 mm). It can be concluded that patch Silver Nanoparticles and Chitosan with Cellulose Nanofibers carriers (SNCCN) have good antibacterial activity at a concentration of 9:1 in the category of strong inhibition (10-20 mm).
Antibiotic Use in Cesarean Section and Hysterectomy Procedure: Qualitative and Quantitative Assessment Andika Dwi Mahendra
Indonesian Journal of Pharmaceutical and Clinical Research Vol. 4 No. 2 (2021): Indonesian Journal of Pharmaceutical and Clinical Research (IDJPCR) Vol. 04, No
Publisher : Talenta Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/idjpcr.v4i2.6235

Abstract

Antibiotic resistance is global issue and the incident is increasing with the use of unwise antibiotic. This study is to describe and evaluate appropriateness of antibiotic prophylaxis selection on Cesarean Section and Hysterectomy procedure. Purpose of study is to evaluate appropiateness of antibiotic selection on cesarean section and hysterectomy. A retrospective study was performed during September 2016 - January 2017 in Private Hospital, Semarang. Data were analized quantitatively using ATC-DDD methodology. Evaluation of antibiotic prophylaxis will be assessed based on The guideline of The American College of Obstetricians and Gynecologists (ACOG) : Antibiotic Prophylaxis for Gynecologic Procedures and The American Society of Health-System Pharmacists (ASHP) : Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. Overall, 90 of 95 patients were given antibiotic prophylaxis. The most frequently used antibiotics were ceftriaxone (69.51 DDD/Patient-days) and ceftazidime (14.95 DDD/Patient-days). Appropriate antibiotic selection based on the guidelines for cesarean section procedure was 1.75% and 6.1% for hysterectomy procedure. The use of antibiotic prophylaxis on cesarean section and hysterectomy procedure was very high and less appropriate in the selection. Almost patient received third-generation cephalosporin instead of first-generation cephalosporin such as cefazolin. cefazolin is more effective and narrow spectrum for infection-causing bacteria of these procedures.
Antifungal Activity of Patch Silver Nanoparticles and Chitosan with Cellulose Nanofibers Carriers against Trichophyton rubrum and Pitysporum ovale Junius Gian Ginting; Poppy Anjelisa Zaitun Hasibuan; Yuandani
Indonesian Journal of Pharmaceutical and Clinical Research Vol. 4 No. 2 (2021): Indonesian Journal of Pharmaceutical and Clinical Research (IDJPCR) Vol. 04, No
Publisher : Talenta Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/idjpcr.v4i2.6295

Abstract

Abstract. Wounds that are not treated and are kept open will provide an entrance for microorganisms from outside that can cause infection. One of the medical needs whose demand continues to increase is wound dressings. Chitosan is known to have wound healing activity by stimulating the formation of new tissue, and silver nanoparticles have good antimicrobial activity. Silver nanoparticles and chitosan with cellulose nanofibers carrier are made in the form of patches with the ratio formula between cellulose nanofibers and chitosan/silver nanoparticles are 1:9, 2:8, 3:8, 4:7, 5:5, 6:4, 7:3, 8:2, 9:1, and 10:0 then tested the antifungal activity against Trichophyton rubrum and Pitysporum ovale for finding the best formula for antifungal activity. The analysis showed that the patch with a ratio of 6:4 had the best antifungal activity against Trichophyton rubrum (14.7±0.1 mm) and a 9:1 patch on the Pitysporum ovale (6.9±0.05 mm) gave a significant difference to negative control (p<0.05). It can be concluded that the Patches Silver Nanoparticle and Chitosan with Cellulose Nanofibers (SNCCN) carriers have good antifungal activity in the inhibitory category.
Plasmodium Resistance to Artemisinin Derivates due to Kelch-3 Gene Mutation Reqgi First Trasi
Indonesian Journal of Pharmaceutical and Clinical Research Vol. 4 No. 2 (2021): Indonesian Journal of Pharmaceutical and Clinical Research (IDJPCR) Vol. 04, No
Publisher : Talenta Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/idjpcr.v4i2.6332

Abstract

Artemisinin class of antimalarial drugs play an important role in controlling falciparum malaria after the emergence of resistance of Plasmodium falciparum to other antimalarial drugs such as chloroquine, sulfadoxine-pyrimethamine and mefloquine. Therefore, the presence of Plasmodium falciparum resistance to this class of drugs is threat to global efforts to eliminate this disease. Resistance of Plasmodium falciparum to artemisinin recently known to be associated with mutations in the propeller domain of the kelch-13 (K13) Plasmodium falciparum gene. The incidence of Plasmodium falciparum resistance due to mutations in the K13 gene, among others, can be found in Cambodia, Laos, Vietnam, China, Myanmar, Thailand and Africa. The presence of mutations in this gene will change the response of Plasmodium falciparum against oxidative stress induced by artemisinin by involving the proteasome-ubiquitin pathway. In addition, mutation K13 will also change the levels of PI3K and PI3P in the body of Plasmodium falciparum. PI3K and PI3P are lipids that essential for the development of Plasmodium falciparum from ring stage to schizont. Resistance to artemisinin will also provide phenotypic changes in the life cycle of Plasmodium falciparum in the form of elongation at the stage ring and transient shortening in trophozoite development. This resistance incident can be overcome, among others by prolonging the duration of treatment (from a 3-day regimen to a 4-day regimen) and combining artemisinin with proteasome inhibitors.
Analysis of Antiretroviral Drugs (ARV) Logistic Management in the Province of Sumatera Utara (Case Study: Regional Public Hospital Dr. Pirngadi Medan And Public Hospital HKBP Balige): English
Indonesian Journal of Pharmaceutical and Clinical Research Vol. 4 No. 2 (2021): Indonesian Journal of Pharmaceutical and Clinical Research (IDJPCR) Vol. 04, No
Publisher : Talenta Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/idjpcr.v4i2.6387

Abstract

Good drug management including planning, procurement, storage, distribution, destruction, recording and reporting is one of the tasks of the North Sumatra Provincial Health Office and HIV Services in the Regency/City. The purpose of this study was to analyze the drug management of the Antiretroviral program drugs in 2019 and 2020 at the Pharmacy Warehouse of the Health Office of North Sumatra Province, the Pharmacy Installation of Pirngadi Hospital Medan, and Pharmacy Installation at HKBP Balige Hospital. The research was conducted in January-April 2021. This research is descriptive with quantitative data obtained retrospectively and concurrently, qualitative data obtained through observation and interviews with informants. The data obtained were analyzed using indicators and compared to standard research results. The results showed in the North Sumatra Provincial Health Office 5 indicators have not met the standards and 9 indicators have met the standards, in Pirngadi Hospital Medan 4 indicators have not met the standards and 8 indicators have met the standards, but have not done the process of planning drug needs, and in HKBP Balige Hospital there are no indicators that meet the standards and do not do the planning of drug needs. The conclusion of this study is drug planning at the North Sumatra Provincial Health Office using the consumption method of the previous period. Pirngadi Hospital Medan and HKBP Balige Hospital did not plan for drug needs. Drug distribution at the North Sumatra Provincial Health Office uses a decentralized system starting in 2020 from the previous centralized system. In Pirngadi Hospital Medan the system is decentralized, while at HKBP Balige Hospital the distribution system is centralized.

Page 1 of 1 | Total Record : 6

 1 

Filter by Year

2021 2021


Reset
Filter By Issues
All Issue Vol. 5 No. 2 (2022): Indonesian Journal of Pharmaceutical and Clinical Research Vol. 5 No. 1 (2022): Indonesian Journal of Pharmaceutical and Clinical Research Vol. 4 No. 2 (2021): Indonesian Journal of Pharmaceutical and Clinical Research (IDJPCR) Vol. 04, No Vol. 4 No. 1 (2021): Indonesian Journal of Pharmaceutical and Clinical Research Vol. 3 No. 2 (2020): Indonesian Journal of Pharmaceutical and Clinical Research Vol. 3 No. 1 (2020): Indonesian Journal of Pharmaceutical and Clinical Research Vol. 2 No. 2 (2019): Indonesian Journal of Pharmaceutical and Clinical Research Vol. 2 No. 1 (2019): Indonesian Journal of Pharmaceutical and Clinical Research Vol. 1 No. 2 (2018): Indonesian Journal of Pharmaceutical and Clinical Research Vol. 1 No. 1 (2018): Indonesian Journal of Pharmaceutical and Clinical Research